One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials
I.AttiliA.PassaroF.de Marinis
Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease
J.Remon1L.E.L.Hendriks2P.Bironzo3
Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force
B.C.Özdemir12S.Oertelt-Prigione34A.A.Adjei5S.Borchmann6J.B.Haanen7A.Letsch8O.Mir9A.Quaas10R.H.A.Verhoeven11A.D.Wagner12
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
S.Popat12P.Baas34C.Faivre-Finn5N.Girard6A.G.Nicholson27A.K.Nowak89I.Opitz10A.Scherpereel11M.Reck12ESMO Guidelines Committee
A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer
G.Middleton1H.Robbins1F.Andre23C.Swanton45
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
C.Corti12G.Antonarelli12F.Scotté34J.P.Spano5J.Barrière6J.M.Michot7F.André8G.Curigliano12
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
J.Niu1C.Maurice-Dror2D.H.Lee3D.-W.Kim4A.Nagrial56M.Voskoboynik7H.C.Chung8K.Mileham9U.Vaishampayan10D.Rasco11T.Golan12T.M.Bauer13A.Jimeno14V.Chung15E.Chartash16M.Lala17Q.Chen18J.A.Healy16M.-J.Ahn19
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R.A.Soo1†J.-Y.Han2†U.Dafni34B.C.Cho5C.M.Yeo6E.Nadal7‡E.Carcereny8‡J.de Castro9‡M.A.Sala10‡R.Bernabé11‡L.Coate12§M.Provencio Pulla13‡R.Garcia Campelo14‡S.Cuffe15§S.M.S.Hashemi16M.Früh1718¶B.Massuti19‡J.Garcia-Sanchez20‡…Byoung ChulCho
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
R.Kim1†M.Kwon2†M.An3†S.T.Kim1S.A.Smith4A.B.Loembé4P.G.S.Mortimer4J.Armenia4N.Lukashchuk4N.Shah4E.Dean4W.-Y.Park56J.Lee17
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G.V.Long1234A.Arance5L.Mortier6P.Lorigan78C.Blank9P.Mohr10J.Schachter11J.-J.Grob12M.Lotem13M.R.Middleton14B.Neyns15N.Steven16A.Ribas17E.Walpole1819M.S.Carlino120C.Lebbe21M.Sznol22E.Jensen23…C.Robert2425
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
J.Tanizaki1K.Yonemori2K.Akiyoshi3H.Minami4H.Ueda5Y.Takiguchi6Y.Miura7Y.Segawa8S.Takahashi9Y.Iwamoto10Y.Kidera11K.Fukuoka11A.Ito12Y.Chiba11K.Sakai13K.Nishio13K.Nakagawa1H.Hayashi1
Letter to the Editor for ‘Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study’
N.Harbeck1P.Rastogi2A.Shahir3S.Johnston4J.O'Shaughnessy5
VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
T.André1A.Falcone2Y.Shparyk3F.V.Moiseenko4E. PoloMarques5T.Csoszi6A. CamposBragagnoli7G.Liposits8E.Chmielowska9P.Aubel10L.MartÃn-Fernández11R.Fougeray12N.Causse-Amellal13M.P.Saunders14
